Tracy Yuen1, Marie-Josée Brouillette, Lesley K Fellows, Ronald J Ellis, Scott Letendre, Robert Heaton, Nancy Mayo. 1. *Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Québec, Canada;†Division of Clinical Epidemiology, McGill University Health Center, Montreal, Québec, Canada;‡Chronic Viral Illness Service, McGill University Health Centre and Department of Psychiatry, McGill University, Montreal, Québec, Canada;§Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montreal, Québec, Canada;Departments of ‖Neurosciences; and¶Psychiatry, University of California San Diego, San Diego, CA; and#HIV Neurobehavioural Research Centre, University of California San Diego, San Diego, CA.
Abstract
BACKGROUND: Little is known about the predictors of neurocognitive decline in HIV+ individuals with good virological control. Identification of modifiable risk factors would allow targeted interventions to reduce the risk of decline in higher risk individuals. The objective of this study was to develop a risk index to predict neurocognitive decline over 3 years in aviremic HIV+ individuals. METHODS: As part of the CNS HIV Anti-Retroviral Therapy Effects Research (CHARTER) study, HIV+ adults completed clinical evaluation and neuropsychological tests every 6 months. Group-based trajectory analysis was used to detect patterns of neurocognitive change; individuals who deteriorated ≥ 0.5 SD on at least one neuropsychological test were considered decliners. Multiple logistic regression was used to identify baseline sociodemographic, clinical, biological, and lifestyle factors associated with decline in the subgroup that was consistently aviremic during the first 3 years. A risk index was developed using the beta-coefficients from the final regression model. RESULTS: Neurocognitive decline occurred in 23 of 191 (12%) participants followed longitudinally. The baseline factors that predicted decline were glomerular filtration rate ≤50 mL/min, known duration of HIV infection ≥15 years, education ≤12 years, and cerebrospinal fluid protein >45 mg/dL. CONCLUSIONS: Using this analytic approach, neurocognitive decline was uncommon in this sample of aviremic HIV+ individuals. The 3-year risk of decline ranged from 2% in those with no risk factors to 95% in those with all 4. The strongest predictor was glomerular filtration rate, also a predictor of cardiovascular disease. This raises the possibility that controlling vascular risk factors could reduce the risk of neurocognitive decline.
BACKGROUND: Little is known about the predictors of neurocognitive decline in HIV+ individuals with good virological control. Identification of modifiable risk factors would allow targeted interventions to reduce the risk of decline in higher risk individuals. The objective of this study was to develop a risk index to predict neurocognitive decline over 3 years in aviremic HIV+ individuals. METHODS: As part of the CNS HIV Anti-Retroviral Therapy Effects Research (CHARTER) study, HIV+ adults completed clinical evaluation and neuropsychological tests every 6 months. Group-based trajectory analysis was used to detect patterns of neurocognitive change; individuals who deteriorated ≥ 0.5 SD on at least one neuropsychological test were considered decliners. Multiple logistic regression was used to identify baseline sociodemographic, clinical, biological, and lifestyle factors associated with decline in the subgroup that was consistently aviremic during the first 3 years. A risk index was developed using the beta-coefficients from the final regression model. RESULTS: Neurocognitive decline occurred in 23 of 191 (12%) participants followed longitudinally. The baseline factors that predicted decline were glomerular filtration rate ≤50 mL/min, known duration of HIV infection ≥15 years, education ≤12 years, and cerebrospinal fluid protein >45 mg/dL. CONCLUSIONS: Using this analytic approach, neurocognitive decline was uncommon in this sample of aviremic HIV+ individuals. The 3-year risk of decline ranged from 2% in those with no risk factors to 95% in those with all 4. The strongest predictor was glomerular filtration rate, also a predictor of cardiovascular disease. This raises the possibility that controlling vascular risk factors could reduce the risk of neurocognitive decline.
Authors: Erin E Sundermann; Mariam A Hussain; David J Moore; Steven Horvath; David T S Lin; Michael S Kobor; Andrew Levine Journal: J Neurovirol Date: 2019-07-08 Impact factor: 2.643
Authors: Violet Awori; Gertrude Nakigozi; Alice Kisakye; James Batte; Aggrey Anok; Richard Mayanja; Noeline Nakasujja; Kevin R Robertson; Ronald H Gray; Maria J Wawer; Ned Sacktor; Deanna Saylor Journal: J Neurovirol Date: 2019-11-12 Impact factor: 2.643
Authors: Felicia C Chow; Asya Lyass; Taylor F Mahoney; Joseph M Massaro; Virginia A Triant; Kunling Wu; Baiba Berzins; Kevin Robertson; Ronald J Ellis; Katherine Tassiopoulos; Babafemi Taiwo; Ralph B D'Agostino Journal: Clin Infect Dis Date: 2020-12-15 Impact factor: 9.079
Authors: Jessica L Montoya; Laura M Campbell; Emily W Paolillo; Ronald J Ellis; Scott L Letendre; Dilip V Jeste; David J Moore Journal: J Acquir Immune Defic Syndr Date: 2019-01-01 Impact factor: 3.731
Authors: Yang Qu; Andrea Weinstein; Zheng Wang; Yu Cheng; Lawrence Kingsley; Andrew Levine; Eileen Martin; Cynthia Munro; Ann B Ragin; Leah H Rubin; Ned W Sacktor; Eric C Seaberg; James T Becker Journal: AIDS Date: 2022-01-01 Impact factor: 4.177